Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas
Status:
Withdrawn
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether therapy with farletuzumab is effective and
safe in the treatment of resectable, non-functioning pituitary adenomas.